Incidence and predictors of major arrhythmic events after acute myocarditis complicated by ventricular arrhythmias: A systematic review and meta-analysis.

Heart RhythmApr 13, 2026 (epub)
Clinical ResearchCardiology

Soundous M'Rabet, Elisé G Kaboré, Moshe Rav-Acha et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined recurrence of major arrhythmic events after acute myocarditis complicated by sustained ventricular tachycardia or ventricular fibrillation. Eight observational studies including 355 patients were analyzed, with a mean pooled follow-up of 3.8 years (95% confidence interval, 2.7-5.1). Major arrhythmic events occurred in 46.4% (95% confidence interval, 38.1-54.9; I² = 50.0). The assessed demographic, clinical, imaging, and pre-discharge ICD factors did not consistently predict recurrence.

Key findings

  • Major arrhythmic events occurred in 46.4% of patients (95% confidence interval, 38.1-54.9; I² = 50.0).
  • Mean pooled follow-up was 3.8 years (95% confidence interval, 2.7-5.1).
  • Age, sex, comorbidities, cardiovascular risk factors, and ICD implantation before discharge were not associated with follow-up events.
  • Reduced left ventricular ejection fraction and the presence or localization of late gadolinium enhancement were not predictive.

Why it matters

The substantial recurrence rate indicates that patients with sustained ventricular arrhythmias during acute myocarditis may remain at meaningful arrhythmic risk after discharge. The absence of consistent predictors among the factors assessed highlights uncertainty in post-discharge risk stratification and the need for better evidence to inform assessment.

What to keep in mind

The evidence came from eight observational studies, and the authors call for larger multicenter cohorts with standardized criteria. The pooled estimate showed moderate heterogeneity (I² = 50.0).

Source

Published in Heart Rhythm. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.